Hep B Liver Cancer Risk Comparable With Tenofovir, Entecavir
Chronic hepatitis B patients face similar risk liver cancer risks whether treated with tenofovir or entecavir, according to a systematic review and meta-analysis.
Related Articles
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Maralixibat improved pruritus and predictors of native liver survival in PFIC (eg, serum bile acids). Maralixibat represents a non-surgical, pharmacological option to interrupt the enterohepatic…
Prophylactic abdominal drainage after distal pancreatectomy (PANDORINA): an international, multicentre, open-label, randomised controlled, non-inferiority trial
A no-drain policy is safe in terms of major morbidity and reduced the detection of grade B or C POPF, and should be the new…
Scottish Parliament votes to increase minimum unit price for alcohol
On April 17, 2024, Scotland’s Parliament approved a 30% increase to the price per unit of alcohol sold in the country. The ruling means the…
U.S. Lags Behind Other Countries in Hepatitis-C Treatment
Despite an arsenal of drugs, many Americans are still unaware of their infections until it’s too late. A Biden initiative languishes without Congressional approval.
Dietary Interventions Beat Medication in IBS Treatment
Both a low-FODMAPs and low-carb diet led to a larger decrease in symptom severity
Dietary interventions a promising first line treatment for IBS
Dietary interventions such as low FODMAP should be considered a potential first-line treatment for patients with IBS, outperforming symptom-targeted medication in reducing symptom severity, a…
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial
Odevixibat could be an efficacious non-surgical intervention to improve pruritus, reduce serum bile acids, and enhance the standard of care in patients with Alagille syndrome.…
Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa – The Lancet Gastroenterology & Hepatology in conversation with
Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00449-1?dgcid=buzzsprout_icw_podcast_generic_langas
Urgent action needed to achieve viral hepatitis elimination
The headline figures from WHO’s 2024 Global Hepatitis Report, released at the World Hepatitis Summit in Lisbon, Portugal, on April 9, make for stark reading.…
Urgent action needed to achieve viral hepatitis elimination
The headline figures from WHO’s 2024 Global Hepatitis Report, released at the World Hepatitis Summit in Lisbon, Portugal, on April 9, make for stark reading.…